Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.Presenters:Susan Buchbinder, MDClinical ProfessorDepartments of Medicine, Epidemiology and BiostatisticsUniversity of California, San FranciscoDirector, Bridge HIVSan Francisco Department of Public HealthSan Francisco, California Jontraye Davis, MHA, PMD ProCommunity Program Manager FHI 360Adjunct InstructorNorth Carolina Central UniversityDurham, North CarolinaSpecial Commentator: Jerome H. Kim, MDDirector GeneralInternational Vaccine InstituteSeoul, South KoreaLink to full series:https://bit.ly/3ytytMYLink to the HIV unmuted series from IAS:https://bit.ly/3f5qC0dContent is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related